Key points from article :
Telocyte, a gene therapy developer, securing new investment, taking telomerase gene therapy to the clinic, and its potential in cardiovascular disease.
Telocyte recently published a new paper describing a unified model of age-related cardiovascular disease, is primarily focused on developing a gene therapy for Alzheimer’s.
Clinical trials by 2025.
“Ultimately, all age-related diseases are our targets, and luckily, we now have an investor who sees exactly that sort of potential,” says Michael Fossel, founder and president.
Telomerase gene therapy is a promising intervention due to its potential to prevent and reverse cell senescence.
“We showed some 25 years ago that we could reverse aging in human cells in the laboratory, so we know we can do this in tissues and organisms too.” he added.
“But can we do it in human patients? ... So, we’ll see,” he says.
